Head to Head Comparison: PAVmed (NASDAQ:PAVM) and Biostage (NASDAQ:BSTG)

PAVmed (NASDAQ:PAVM) and Biostage (OTCMKTS:BSTG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

4.9% of PAVmed shares are owned by institutional investors. Comparatively, 0.2% of Biostage shares are owned by institutional investors. 34.4% of PAVmed shares are owned by company insiders. Comparatively, 6.7% of Biostage shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

PAVmed has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Biostage has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.

Profitability

This table compares PAVmed and Biostage’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PAVmed N/A N/A -140.97%
Biostage N/A -388.10% -274.72%

Earnings & Valuation

This table compares PAVmed and Biostage’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PAVmed N/A N/A -$17.97 million N/A N/A
Biostage $80,000.00 219.65 -$7.53 million N/A N/A

Biostage has higher revenue and earnings than PAVmed.

Analyst Ratings

This is a breakdown of recent ratings for PAVmed and Biostage, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PAVmed 0 0 1 0 3.00
Biostage 0 0 0 0 N/A

PAVmed presently has a consensus price target of $3.00, suggesting a potential upside of 244.83%. Given PAVmed’s higher possible upside, analysts clearly believe PAVmed is more favorable than Biostage.

Summary

PAVmed beats Biostage on 6 of the 9 factors compared between the two stocks.

About PAVmed

PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.

About Biostage

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.